drugset / Trial / NCT02593409

HIV PrEP Priming of Immune Effectors

NCT02593409

Phase 4 Unknown 220 enrolled MRC/UVRI and LSHTM Uganda Research Unit
NaSingle-groupOpen-labelPrevention

Summary

Can HIV-specific immunity develop in HIV uninfected humans exposed to HIV whilst receiving antiretroviral pre-exposure prophylaxis (PrEP)? Investigators will investigate this possibility in commercial sex workers in Kampala who will be receiving Truvada PrEP for one year.

Timeline

Start
2017-05-25
Primary completion
2018-04
Completion
2018-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenofovir disoproxil fumarate Small molecule 300 mg Oral
Subject emtricitabine Other / unclassified 200 mg Oral